Search | Clinical Trials Finder

Conditions: Neuroblastoma Recurrent
Interventions: Temozolomide, Irinotecan, hu14.18K322A, N803, Sargramostim; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 30 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 5
States / cities: San Francisco, California • Aurora, Colorado • Ann Arbor, Michigan + 2 more

Conditions: Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions: Interleukin-15 Superagonist (N-803), CIML NK cell Infusion, Ipilimumab, Cetuximab; Drug · Biological
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: COVID-19
Interventions: N-803, Saline; Biological · Other
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Lynwood, California

Conditions: Colorectal Carcinoma, Colorectal Neoplasm, Lynch Syndrome
Interventions: Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5, Biopsy Procedure, Biospecimen Collection, Colonoscopy, Nogapendekin Alfa, Placebo Administration, Questionnaire Administration; Biological · Procedure · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 13
States / cities: Phoenix, Arizona • Tucson, Arizona • San Francisco, California + 10 more

Conditions: Long COVID
Interventions: N-803 (IL-15 Superagonist); Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Non Hodgkin's Lymphoma Refractory/Relapsed
Interventions: N803, CD19t-haNK suspension, Cyclophosphamide, Fludarabine, Rituximab; Drug · Biological
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Newport Beach, California • Tyler, Texas

Conditions: Bladder Cancer
Interventions: N-803 and BCG, N-803; Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2029
U.S. locations: 28
States / cities: Anchorage, Alaska • Little Rock, Arkansas • Los Angeles, California + 25 more

Conditions: Prostate Cancer, Metastatic Prostate Cancer
Interventions: Sipuleucel-T, N803; Biological
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Neoplasm, Advanced Solid Tumor, Solid Tumor, Non-metastatic Castration-resistant Prostate Cancer
Interventions: M7824, N-803, MVA-BN-Brachyury, FPV-Brachyury, Epacadostat, Acetaminophen, Ibuprofen, Naproxen, Benadryl, EKG, Bone scan, CT chest, abdomen and pelvis, MRI; Biological · Drug · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Metastatic Urothelial Carcinoma, Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Urothelial Cancer, Bladder Cancer
Interventions: Nogapendekin Alfa Inbakicept (NAI), enfortumab vedotin (EV), Pembrolizumab; Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions: PD-L1 t-haNK, Cetuximab, NAI; Biological · Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Gastroesophageal Junction (GEJ) Cancers, Advanced HNSCC
Interventions: N-803, Pembrolizumab, PD-L1 t-haNK; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Subjects
Interventions: N-803; Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: El Segundo, California

Conditions: Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinomas
Interventions: Montanide (Registered Trademark) ISA-51 VG Adjuvant, H1299 Cell Lysates, N-803, Ventana PD-L1 (SP263 or SP142) assay; Biological · Drug · Device
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Squamous Cell Carcinoma
Interventions: Aldoxorubicin HCl, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK for infusion, Avelumab, bevacizumab, Capecitabine, Cetuximab, Cisplatin, Cyclophosphamide, Fluorouracil, Leucovorin, nab-Paclitaxel, Necitumumab, SBRT, N-803; Drug · Biological · Procedure
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: El Segundo, California

Conditions: NSCLC Stage IV
Interventions: N-803, Tislelizumab, Docetaxel, Prior failed checkpoint inhibitor; Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 19
States / cities: Springdale, Arkansas • El Segundo, California • Fountain Valley, California + 14 more

Conditions: Recurrent Prostate Cancer, Prostate Cancer
Interventions: N-803, ETBX-71 Vaccine, 18F-DCFPyL; Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS)
Interventions: N-803; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma
Interventions: Rituximab, N-803; Biological
Lead sponsor: Altor BioScience; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 4
States / cities: Minneapolis, Minnesota • St Louis, Missouri • Columbus, Ohio + 1 more

Conditions: Long COVID, Long COVID Syndrome, Long Covid 19
Interventions: Anktiva; Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: El Segundo, California

Conditions: Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Cobalamin, Dexamethasone, Docetaxel, Folic Acid, Gemcitabine, Nogapendekin Alfa, Pembrolizumab, Pemetrexed, Ramucirumab; Dietary Supplement · Drug · Biological
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 350
States / cities: Birmingham, Alabama • Goodyear, Arizona • Little Rock, Arkansas + 280 more

Conditions: Myxoid Liposarcoma, Round Cell Liposarcoma, Synovial Sarcoma
Interventions: Biospecimen Collection, Computed Tomography, Leukapheresis, Magnetic Resonance Imaging, Nogapendekin Alfa Inbakicept, X-Ray Imaging; Procedure · Biological
Lead sponsor: Seth Pollack; Other
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Metastatic Colorectal Cancer
Interventions: Retifanlimab, Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform, N-803, SX-682; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hiv, HIV Infections, AIDS
Interventions: N-803; Biological
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma

CIML NK Cell in Head & Neck Cancer

Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19

Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome

A Study to Assess Anktiva in Patients With Long Covid-19.

Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer

Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer

Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By Apheresis

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy

Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT

QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

A Study to Examine Anktiva for the Treatment of COVID-19.

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

Effect of N-803 on B Cell Follicles in Antiretroviral Treated HIV Disease